Synonyms for serostim or Related words with serostim

saizen              geniquin              zorbtive              genotropin              somatropin              genimune              mecasermin              humatrope              geref              somatropins              gentropin              forteo              increlex              gilenia              opebacan              serono              leucomax              humegon              omnitrope              pegvisomant              somalgen              gerbin              somavert              repronex              sanexon              valtropin              cardeva              neumega              fertinex              savient              accretropin              stavudinie              becaplermin              galsulfase              xerecept              reteplases              velafermin              genentechinc              zofran              nestacort              somazon              iluvien              neuprex              sarapep              xgeva              somenopor              sonap              rinfabate              actimmune              beclapermin             

Examples of "serostim"
Serostim (recombinant DNA somatropin) is Serono's brand name prescription drug form of synthetic growth hormone, marketed for AIDS wasting.
Drugs they market include Erbitux, UFT, Rebif, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive, Luveris, Saizen, Serostim, Glucophage, Concor and Euthyrox. Raptiva was withdrawn in 2007.
The settlement will pay consumers of Serostim who paid the full cash amount or a co-payment as part of their medical treatment.
In December 2007, the U.S. District Court of Massachusetts settled a class-action lawsuit that involved Merck Serono and the drug Serostim. The lawsuit claims that Merck Serono encouraged doctors to prescribe Serostim off-label for criteria that were not approved by the FDA. Merck Serono denies these claims and any liability. However, Merck Serono has entered into a settlement "solely to avoid the further expense, inconvenience, burden, and uncertainty of these lawsuits."
In 2005, Serono agreed to a $704 million settlement with the Department of Justice to resolve civil and criminal allegations that the company engaged in a fraudulent scheme to promote the drug Serostim for off-label uses and paid out illegal kickbacks for prescribing the drug in violation of the False Claims Act. The settlement is, to date, the sixth largest pharmaceutical settlement in U.S. history.
In developed countries, many online doctors prescribe so-called ‘lifestyle drugs’, such as for weight loss, hair loss or erectile dysfunction. The RPSGB has identified the most popular products prescribed online as Prozac (an antidepressant), Viagra (for erectile dysfunction), Valium (a tranquiliser), Ritalin (a psychostimulant), Serostim (a synthetic growth hormone) and Provigil (a psychostimulant). A study in the USA has also shown that antibiotics are commonly available online without prescription.
Serono, a Swiss biotechnology company, obtained approval from the FDA for the drug Serostim in 1996 to treat AIDS wasting, a condition in which AIDS patients experience rapid weight loss. However, around the same time, the advent of more robust protease inhibitors that could interact in AIDS cocktails to markedly slow the advancement of the syndrome led to a decline in symptoms of AIDS wasting and, consequently, demand for Serostim. As a result, according to prosecutors, Serono devised a marketing scheme by which the definition of AIDS wasting would be changed to measure a loss in "body cell mass." The company then created a computerized medical test designed to detect loss of body cell mass and thereby diagnose AIDS wasting even in patients who had not experienced any weight loss. Serono ultimately agreed to pay $704 million to resolve all civil and criminal liability. Five whistleblowers, all former employees of Serono, initiated complaints under the False Claims Act, ultimately leading to the government's investigation. The whistleblowers shared in a $51 million reward from the settlement.
Within a few years, GH treatment had become more common and competitors entered the market. Eli Lilly launched a competing natural sequence growth hormone (Humatrope). Pharmacia (formerly Kabi, now Pfizer) introduced Genotropin. Novo Nordisk introduced Norditropin. Serono (now EMD Serono) introduced Saizen and Serostim. Ferring has introduced Zomacton. Genentech eventually introduced another HGH product, Nutropin, and stopped making Protropin in 2004. Price competition had begun. Teva, which is primarily a generics company, has introduced Tev-tropin. Chinese companies have entered the market as well and have introduced more pricing competition: NeoGenica BioScience Ltd. introduced Hypertropin, GeneScience introduced Jintropin, Anhui Anke Biotechnology introduced Ansomone, Shanghai United Kefei Biotechnology introduced Kefei HGH, and Hygene BioPharm introduced Hygetropin. These are all recombinant human growth hormone products and they have competed with various marketing strategies. Most children with severe deficiency in the developed world are now likely to have access to a pediatric endocrinologist and be diagnosed and offered treatment.
The United States has a growing problem with counterfeit drugs. In 2012, tainted steroids killed 11 people near Boston and sickened another 100. In another case, vials of the cancer medicine Avastin were found to contain no active ingredients. The vials were sourced in Turkey, shipped to Switzerland, then Denmark, finally to the United Kingdom from which they were exported to U.S. wholesale distributors. The Wall Street Journal reported that the U.S. wholesale distributor was hired by Canada Drugs, which also owns, a retail pharmacy website that sells prescription medication internationally, with a focus on the American market. In 2007-08, 149 Americans died from a contaminated blood thinner called Heparin that was legally imported into the United States. Investigated by the FDA Office of Criminal Investigations, the Albers Medical investigation is the most prolific example to date. On August 21, 2005, the U.S. Attorney’s Office for the Western District of Missouri issued a press release announcing that three businesses and eleven individuals were indicted for their involvement in a $42 million conspiracy to sell counterfeit, smuggled and misbranded Lipitor and other drugs and for participating in a conspiracy to sell stolen drugs. As part of this investigation, FDA initiated a recall of more than 18 million Lipitor tablets, which ranks as the largest recall in the history of criminal investigations of counterfeit medications. Participants in this scheme conspired to purchase and sell counterfeit, misbranded and illegally imported drugs. Foreign versions of Lipitor and Celebrex were smuggled into the U.S. from South America and re-sold after being re-packaged to conceal the true origin of the drugs. Counterfeit Lipitor also was manufactured in South America and then smuggled into the U.S. where it was co-mingled with the genuine foreign Lipitor and sold in the U.S. In addition, participants conspired to buy, sell and traffic almost eight million dollars worth of stolen Glaxo Smith Kline and Roche drugs, using fake pedigrees to launder the drugs and thereby concealing that they were stolen. There also were charges related to the sale of counterfeit Procrit, as well as counterfeit and misbranded Serostim and Neupogen. Procrit is an injectable drug used in the treatment of anemia and Neupogen is an injectable drug used by cancer patients to stimulate the production of white blood cells in order to decrease the incidence of infections.